Following a substantial surge of over 11% yesterday, EDGE MEDICAL-B (02675) has climbed more than 7% again. At the time of writing, the stock was up 7.34%, trading at HK$70.95, with a turnover of HK$48.1849 million. On the news front, the National Healthcare Security Administration recently issued the "Guidelines for the Establishment of Price Items for Surgical and Therapeutic Auxiliary Operation Medical Services (Trial)", which establishes a unified national pricing framework for innovative medical technologies such as surgical robots, specialized consumables for energy devices, and remote surgery. China Post Securities believes that this nationally unified fee structure for robotic surgery will serve as a critical turning point for the commercialization of the surgical robot industry. According to a Northeast Securities research report, EDGE MEDICAL is one of the top two domestic surgical robot companies, with its multi-port, single-port, and natural orifice腔镜 robots rapidly gaining volume both domestically and internationally; the company ranked first among domestic players in the number of中标 for domestic腔镜 robot tenders in 2025. Its remote surgery modality received NMPA approval in November 2025 and achieved a milestone of 500 procedures in October 2025.